RxDoctor Payments Data

Jennifer Livingston, PA

Physician Assistant · Livingston, TXNPI 1679513907

Payments from drug & device makers

$2,479in general payments, 2019–2025

Across 129 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$542
  • AbbVie$322
  • Vanda Pharmaceuticals Inc.$209
  • Mylan Specialty L.p.$191
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$164
  • Viatris Specialty LLC$130
  • plus $922 from 20 others

What the payments were for

  • Food & beverage$2,43298%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,479 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$28,772
Medicare patients
100
Services billed
654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide64$75,866
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$50,282
EliquisApixaban42$46,369
JanuviaSitagliptin Phosphate24$30,960
JardianceEmpagliflozin30$30,155
OzempicSemaglutide23$26,918
TrulicityDulaglutide13$14,734
FarxigaDapagliflozin Propanediol13$11,192
SymbicortBudesonide/Formoterol Fumarate28$10,259
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$9,616
TrulancePlecanatide12$9,457
Albuterol Sulfate HfaAlbuterol Sulfate159$8,054
ShingrixVaricella-Zoster Ge/As01b/Pf23$5,081
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$4,354
Gabapentin164$3,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$44$90,60077 claims
GSKTrelegy Ellipta, Shingrix$542$55,36374 claims
PfizerEliquis$53$46,36942 claims
MerckJanuvia$15$30,96024 claims
AstraZenecaFarxiga, Symbicort$96$21,45241 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$164$9,45712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Livingston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →